IDEAYA Biosciences Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 IDEAYA Biosciences Inc 公司

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

IDEAYA Biosciences Inc簡介



公司代碼IDYA

公司名稱IDEAYA Biosciences Inc

上市日期May 23, 2019

CEOHata (Yujiro S)

員工數量131

證券類型Ordinary Share

年結日May 23

公司地址7000 Shoreline Ct, Suite 350

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94080

電話16504436209

網址https://www.ideayabio.com/

公司代碼IDYA

上市日期May 23, 2019

CEOHata (Yujiro S)

IDEAYA Biosciences Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Joshua Bleharski, Ph.D.

Chief Financial Officer

--

Mr. Yujiro S. Hata

President, Chief Executive Officer, Director

--

Mr. Andres Ruiz Briseno, CPA

Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations

--

Ms. Wendy L. Yarno

Independent Director

--

Mr. Scott W. Morrison, CPA

Independent Director

--

Dr. Terry J. Rosen, Ph.D.

Independent Chairman of the Board

--

Dr. Jeffrey L. (Jeff) Stein, Ph.D.

Independent Director

--

Dr. M. Garret Hampton, Ph.D.

Independent Director

--

Dr. Catherine J. Mackey, Ph.D.

Independent Director

--

Dr. Michael A. White, Ph.D.

Chief Scientific Officer

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Joshua Bleharski, Ph.D.

Chief Financial Officer

--

Mr. Yujiro S. Hata

President, Chief Executive Officer, Director

--

Mr. Andres Ruiz Briseno, CPA

Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations

--

Ms. Wendy L. Yarno

Independent Director

--

Mr. Scott W. Morrison, CPA

Independent Director

--

Dr. Terry J. Rosen, Ph.D.

Independent Chairman of the Board

--

收入明細

FY2025

FY2024

FY2024Q4

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

218.71M

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 5月10日週日

持股股東

股東類型

持股股東

佔比

Fidelity Management & Research Company LLC

14.97%

Janus Henderson Investors

8.18%

BlackRock Institutional Trust Company, N.A.

7.45%

Capital Research Global Investors

6.01%

State Street Investment Management (US)

4.71%

其他

58.69%

持股股東

佔比

Fidelity Management & Research Company LLC

14.97%

Janus Henderson Investors

8.18%

BlackRock Institutional Trust Company, N.A.

7.45%

Capital Research Global Investors

6.01%

State Street Investment Management (US)

4.71%

其他

58.69%

股東類型

持股股東

佔比

Investment Advisor

49.16%

Investment Advisor/Hedge Fund

34.40%

Hedge Fund

18.19%

Venture Capital

4.64%

Research Firm

3.40%

Corporation

1.52%

Individual Investor

0.89%

Pension Fund

0.86%

Bank and Trust

0.43%

機構持股



更新時間: 4月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q1

518

97.55M

111.03%

-12.93M

2025Q4

494

96.98M

110.62%

-16.62M

2025Q3

460

105.73M

120.62%

-11.57M

2025Q2

449

101.70M

116.06%

-6.32M

2025Q1

454

97.81M

111.68%

-11.15M

2024Q4

442

95.26M

108.96%

-7.87M

2024Q3

426

95.20M

112.79%

+2.56M

2024Q2

409

85.26M

112.59%

-3.91M

2024Q1

388

81.45M

108.91%

-1.44M

2023Q4

351

68.31M

105.94%

-512.62K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Fidelity Management & Research Company LLC

13.15M

14.97%

+3.42K

+0.03%

Dec 31, 2025

Janus Henderson Investors

7.19M

8.18%

+758.12K

+11.79%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

6.54M

7.45%

+208.10K

+3.28%

Dec 31, 2025

Capital Research Global Investors

5.28M

6.01%

-1.27M

-19.43%

Dec 31, 2025

State Street Investment Management (US)

4.13M

4.71%

+893.71K

+27.58%

Dec 31, 2025

Baker Bros. Advisors LP

3.62M

4.12%

+343.38K

+10.48%

Dec 31, 2025

Logos Global Management LP

3.13M

3.56%

+875.00K

+38.89%

Dec 31, 2025

Federated Hermes Global Investment Management Corp.

3.40M

3.87%

-1.23M

-26.59%

Dec 31, 2025

Adage Capital Management, L.P.

2.80M

3.19%

-100.09K

-3.45%

Dec 31, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Tema Oncology ETF

3.49%

ALPS Medical Breakthroughs ETF

1.16%

Virtus LifeSci Biotech Clinical Trials ETF

0.97%

Invesco Dorsey Wright Healthcare Momentum ETF

0.83%

State Street SPDR S&P Biotech ETF

0.72%

First Trust Innovation Leaders ETF

0.7%

Direxion Daily S&P Biotech Bull 3X Shares

0.45%

ProShares Ultra Nasdaq Biotechnology

0.38%

Avantis US Small Cap Equity ETF

0.29%

Invesco Nasdaq Biotechnology ETF

0.27%

Tema Oncology ETF

佔比3.49%

ALPS Medical Breakthroughs ETF

佔比1.16%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.97%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比0.83%

State Street SPDR S&P Biotech ETF

佔比0.72%

First Trust Innovation Leaders ETF

佔比0.7%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.45%

ProShares Ultra Nasdaq Biotechnology

佔比0.38%

Avantis US Small Cap Equity ETF

佔比0.29%

Invesco Nasdaq Biotechnology ETF

佔比0.27%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據